The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
Articles
Search our media releases, news, safety updates (medicines and medical devices), vaccine safety reports, and notices.
Loading...
Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
- (-) Scheduling (national classification system) (12)
- Advertising (115)
- Regulatory compliance (76)
- Prescription medicines (74)
- COVID-19 (70)
- Therapeutic goods regulation (58)
- Listed medicines (47)
- Legislation (46)
- Non-prescription medicines (46)
- COVID-19 vaccines (36)
- Complementary medicines (28)
- Manufacturing (27)
- Medicine safety (27)
- Vaping hub (26)
- Assessed listed medicines (24)
- Labelling and packaging (16)
- Compliance and enforcement hub (15)
- Over the counter (OTC) medicines (15)
- Australian Register of Therapeutic Goods (ARTG) (14)
- Medicinal cannabis hub (13)
- Import and export (11)
- In Vitro Diagnostic medical devices (IVDs) (11)
- Safety (10)
- Medical devices safety (9)
- Alert/Advisory (8)
- Advisory bodies and committees (5)
- Shortages (4)
- Clinical trials (3)
- Sunscreens (3)
- Weight loss products (2)
- Advanced therapies (1)
- Biological medicines (1)
- Blood and blood components (1)
- Cosmetics (1)
- Fees and payments (1)
- Prescription opioids hub (1)
- Registered complementary medicines (1)
Search
12 result(s) found, displaying 1 to 12
-
NoticesThis instrument is made under section 39 of the current Poisons Standard.
-
NoticesThis instrument is made under section 39 of the current Poisons Standard.
-
NoticesWe are providing a 12-month period of labelling exemptions for signal words for certain Pharmacy medicine and Pharmacist Only medicine products.
-
NoticesThis instrument is the Therapeutic Goods (Poisons Standard) (Benzylpenicillin—Seqirus) Approval 2024.
-
NewsFind out about changes to choline salicylate access, starting from October 2023.
-
NewsStay updated about the commencement of MDMA and psilocybin for the treatment of certain mental illnesses.
-
Media releasesThe TGA has published a final decision to reduce the maximum size of packs for various paracetamol products.
-
Media releasesFrom 1 June 2023, prescribing of oral ivermectin for ‘off-label’ uses will no longer be limited to specialists such as dermatologists, gastroenterologists and infectious diseases specialists.
-
Media releasesThe TGA has today published an interim decision to reduce the maximum pack sizes for various paracetamol products.
-
Media releasesThe TGA has published an independent expert report examining the incidence of serious injury and death from intentional paracetamol overdose.
-
NoticesThis labelling exemption is granted under section 1.1(3) of Part 2 of the current Poisons Standard.
-
Media releasesToday the TGA announced a final decision to down-schedule certain low dose cannabidiol (CBD) preparations